Savient Pharmaceuticals Inc

Type: Company

Name: Savient Pharmaceuticals Inc

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Form 4 SAVIENT PHARMACEUTICALS For: May 22 Filed by: FERRARI LOUIS

StreetInsider.com - Form 4 SAVIENT PHARMACEUTICALS For: May 22 Filed by: FERRARI LOUIS ... [Published Street Insider - May 23 2013]

Entities: Savient Pharmaceuticals Inc, Ferrari SpA

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Centers for Disease Control and Prevention

Belushi, Savient observe Gout Awareness Day

Today is Gout Awareness Day, and Jim Belushi is speaking out about his experiences with the disease.The actor, who has had the rheumatic disease for around 15 years, chaired a roundtable with three other patients talking about living with the disease. ... [Published Medical Marketing And Media - May 22 2013]

Entities: James Belushi, GOUT, Centers for Disease Control and Prevention, Global Healthy Living Foundation

First reported May 19 2013 - Updated May 20 2013 - 1 reports

WuXi PharmaTech Cayman Inc

3 Pharmaceutical Stock Earnings Snapshots

Savient Pharmaceuticals, Inc. ( NASDAQ:SVNT ) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. Adjusted Earnings Per Share increased to $-0.34 in the quarter versus EPS of $-0.49 in the year-earlier ... [Published Wall St. Cheat Sheet - May 19 2013]

Entities: WuXi PharmaTech Cayman Inc, Agilent Technologies Inc, Earnings Per Share, Wall Street

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Savient Pharmaceuticals Reports 1Q 2013 Financial Results

Savient Pharmaceuticals, Inc. reported financial results for the three months ended March 31. In a release dated May 15, the Company said that net sales of Krystexxa (pegloticase) were $4.4 million for the first quarter of 2013, a 6 percent decrease from ... [Published Individual.com - May 20 2013]

Entities: Krystexxa, Savient Pharmaceuticals Inc, Pegloticase, New Jersey Economic Development Authority

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Savient Pharmaceuticals Stock Rating Lowered by William Blair (SVNT)

Savient Pharmaceuticals (NASDAQ: SVNT)Shares of Savient Pharmaceuticals (NASDAQ: SVNT) opened at 0.57 on Friday. Savient Pharmaceuticals has a one year low of $0.48 and a one year high of $2.95. The stock?s 50-day moving average is currently $0.80. The ... [Published American Banking News - May 17 2013]

Entities: Savient Pharmaceuticals Inc, William Blair, Krystexxa

First reported May 15 2013 - Updated May 15 2013 - 2 reports

Savient Pharmaceuticals Down 14.1%, Shares Slide into the Red (SVNT)

Savient Pharmaceuticals (NASDAQ:SVNT) is one of today's worst performing penny stocks, down 14.1% to $0.58 on 5.8x average daily volume. Savient Pharmaceuticals has traded 1.4 million shares thus far today, vs. average volume of 233,000 shares per day. ... [Published Comtex SmarTrend - May 15 2013]

Entities: Savient Pharmaceuticals Inc, Stocks, Penny Stocks, Moving Average, Uric Acid

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Savient Pharmaceuticals, Inc. Reports First Quarter 2013 Financial Results

/PRNewswire/ -- Savient Pharmaceuticals, Inc. SVNT today reported financial results for the three months ended March 31, 2013. Net sales of KRYSTEXXAÂ® (pegloticase) were $4.4 million for the first quarter of 2013, a 6% decrease from the fourth quarter ... [Published BioSpace - May 15 2013]

Entities: Savient Pharmaceuticals Inc, Pegloticase, Krystexxa

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Savient Pharmaceuticals (SVNT) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Savient Pharmaceuticals (NASDAQ: SVNT) posted its quarterly earnings results on Wednesday. The company reported ($0.34) earnings per share for the quarter, missing the analysts? consensus estimate of ($0.31) by $0.03, reports. The company had revenue ... [Published American Banking News - May 15 2013]

Entities: Savient Pharmaceuticals Inc, Krystexxa, Pegloticase, conventional therapy

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Savient Pharma (SVNT): Q1 EPS of -$0.34 misses by $0.03. Revenue of $4.7M. (PR)

:04 AM ET Savient Pharma (SVNT): Q1 EPS of -$0.34 misses by $0.03. Revenue of $4.7M. (PR) ... [Published Seeking Alpha - May 15 2013]

Entities: Savient Pharmaceuticals Inc

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Savient Pharmaceuticals Reports First Quarter 2013 Financial Results

/PRNewswire/ --$ Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three months ended March 31 , 2013.$ Net sales of KRYSTEXXA ® $ (pegloticase) were $4.4 million for the first quarter of 2013, a 6% decrease from the ... [Published Barchart - May 15 2013]

Entities: Savient Pharmaceuticals Inc, Krystexxa, Pegloticase, Current Liabilities, Stocks

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Form 4 SAVIENT PHARMACEUTICALS For: Apr 30 Filed by: CROWLEY Richard

StreetInsider.com - Form 4 SAVIENT PHARMACEUTICALS For: Apr 30 Filed by: CROWLEY Richard ... [Published Street Insider - May 01 2013]

Entities: Savient Pharmaceuticals Inc

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Form 4 SAVIENT PHARMACEUTICALS For: Apr 30 Filed by: Bahrt Kenneth

StreetInsider.com - Form 4 SAVIENT PHARMACEUTICALS For: Apr 30 Filed by: Bahrt Kenneth ... [Published Street Insider - May 01 2013]

Entities: Savient Pharmaceuticals Inc

Quotes

...could cause actual results or events to differ from the forward-looking statements that we make, see the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2013...

Savient Pharmaceuticals Reports First Quarter 2013 Financial Results [Published Barchart - May 15 2013]

...Vivus Board has proven to be poor stewards of shareholder capital," commented Sam Colin, M D , Senior Managing Director at FMC and a Board nominee. "Qsymia's potential is substantial. However, Vivus has badly mismanaged the Qsymia launch, and neither the recent REMS modification nor the addition of a new director will cure the root cause of the failure. Vivus and its shareholders deserve a Board worthy of Qsymia. Our slate of six highly qualified nominees has the independence, the experience, and the plan to fix the Company before time runs out."

First Manhattan Files Preliminary Proxy Materials with SEC for the Election of Six Directors to Vivu [Published Daily Finance - May 01 2013]

"We are pleased that Vivus has chosen to add a new director with large pharma experience and one who has been associated with a long-standing shareholder. It is a sad statement that multiple failed attempts to launch Qsymia, an obesity drug with blockbuster potential, were clearly not enough to prod this Board into action. It was only in response to FMC's campaign to elect our six highly qualified nominees that the current Board has chosen to act."

First Manhattan Comments on Addition to Vivus' Board of Directors [Published Zecco - May 01 2013]

"Bob is a proven leader with an exceptional track record of..."

Savient Announces the Election of Robert G. Savage to its Board of Directors [Published PR Newswire: Health - Dec 05 2012]

More Content

sort by: Date \| Relevance
Form 4 SAVIENT PHARMACEUTICALS For: May 22 File... [Published Street Insider - May 23 2013]
Belushi, Savient observe Gout Awareness Day [Published Medical Marketing And Media - May 22 2013]
Jim Belushi, Savient And CreakyJoints Team Up T... [Published PR Newswire: Health - May 22 2013]
Savient Pharmaceuticals, Inc. (SVNT) - Pharmace... [Published TransWorldNews - May 21 2013]
Savient Pharmaceuticals Reports 1Q 2013 Financi... [Published Individual.com - May 20 2013]
3 Pharmaceutical Stock Earnings Snapshots [Published Wall St. Cheat Sheet - May 19 2013]
3 Pharmaceutical Stock Earnings Snapshots [Published Wall St. Cheat Sheet - May 19 2013]
Savient downgraded to Market Perform from Outpe... [Published Yahoo! Finance - May 17 2013]
Stock Downgrades: Pottery Barn Owner Williams-S... [Published Minyanville - May 17 2013]
Stock Analysts’ Downgrades for May, 17th (AMAT,... [Published American Banking News - May 17 2013]
Savient Pharmaceuticals Stock Rating Lowered by... [Published American Banking News - May 17 2013]
Savient Pharmaceuticals Down 14.1%, Shares Slid... [Published Comtex SmarTrend - May 15 2013]
Unusual 11 Mid-Day Movers 05/15: (MFLR) (CHCI) ... [Published Street Insider - May 15 2013]
Savient Pharmaceuticals Down 14.1%, Shares Slid... [Published Individual.com - May 15 2013]
Savient Pharmaceuticals, Inc. Reports First Qua... [Published BioSpace - May 15 2013]
Savient Pharmaceuticals (SVNT) Announces Quarte... [Published American Banking News - May 15 2013]
Savient Pharma (SVNT): Q1 EPS of -$0.34 misses ... [Published Seeking Alpha - May 15 2013]
Savient Pharmaceuticals Reports First Quarter 2... [Published Barchart - May 15 2013]
Savient Pharmaceuticals Reports First Quarter 2... [Published Financial Services - May 15 2013]
Semi-Annual Changes to the NASDAQ Biotechnology... [Published BizWire Express - May 13 2013]
Savient Pharmaceuticals, Inc. (SVNT): Are Hedge... [Published InsiderMonkey.com - May 03 2013]
Form 4 SAVIENT PHARMACEUTICALS For: Apr 30 File... [Published Street Insider - May 01 2013]
Form 4 SAVIENT PHARMACEUTICALS For: Apr 30 File... [Published Street Insider - May 01 2013]
First Manhattan Files Preliminary Proxy Materia... [Published Daily Finance - May 01 2013]
First Manhattan Responds to VIVUS Board Additio... [Published Equities.com - May 01 2013]
First Manhattan Responds to VIVUS Board Additio... [Published Benzinga.com - May 01 2013]
VIVUS, INC.: First Manhattan Comments on Additi... [Published 4 Traders - May 01 2013]
First Manhattan Comments on Addition to Vivus' ... [Published Zecco - May 01 2013]
Savient Pharmaceuticals: Is Anything Left? [Published Healthcare Sector and Stocks Analysis from Seek ... - Mar 25 2013]
Did These 5 Stocks Miss or Beat Analyst Expecta... [Published Wall St. Cheat Sheet - Mar 23 2013]